Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label study of brentuximab vedotin in Chinese adults with CD30-positive cutaneous T-cell lymphoma
CTR20221677Phase 4Completed
- Sponsor
- Takeda
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of brentuximab vedotin in cutaneous T-cell lymphoma, mycosis fungoides (MF), primary cutaneous anaplastic large cell lymphoma (PCALCL), sponsored by Takeda. Started Jul 2022; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
cutaneous T-cell lymphomamycosis fungoides (MF)primary cutaneous anaplastic large cell lymphoma (PCALCL)
Beyond the preview
Go deeper on CTR20221677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221677.